bear. >> a fly on the set tonight that i killed for you. >> right there, actually. >> no e-mail. i hate e-mail, please. that's me in my meggings. >> that's disturbing. >> what's disturbing about it? yahoo!! price doesn't lie. >> half goat half man. >> i'll stick with general dynamics and pass the ball to pete. >> pete? >> i like these coal names. i like the reaction we saw today. midday, that spike to the upside. anr. >> all right, i'm >> thanks for watching, "mad money" is up next. >> i'm jim cramer and welcome to my world. >> they're nuts! they know nothing! i always have to say there's a bull market somewhere. hey, i'm cramer, welcome to "mad money." my job is not just to entertain, but i'm trying to teach you, to

educate. so call me at 1-800-743-cnbc. do we pay too much attention to apple? do we pay too much attention to the fiscal cliff excluding everything else? with the dow up 15 points, nasdaq rising 5.30%. we talk about how the transports farewell, or how i like the new honey well application. where you should buy the aig over the dip. it's fun for us to puzzle over the strength of hewlett packard. deckers down $3 because of the warm weather impact on uggss that what's behind coach today? that's what i regard as

productive use of my time. but unfortunately, that's not the case for many of you and in many ways, it's not what you need to hear. in fact all those issues i just mentioned, aren't even mildly important after the big things we battle every day. first let's tackle the fiscal cliff. i'm beginning to hear a ton of blow back about how he talk about it too much. jim, give it a rest, will you? i'm getting a feel of how our rise above campaign is still warm, because the politicians aren't going to rise above, stop kidding yourself cramer. yes, yes, yes to my mono vacati without legislation motto. i wish i never had to talk

politics ever. one of the reasons that i started "mad money" was that i would never have to talk politics. that's somethingsona that shouldn't even be discussed on air. i know everybody's hostage to washington these days. there's some trends that can trump the government, health and wellness maybe? breaking up is easy to do stories. better than expected retailers, in the end when it come to the fiscal cliff, to the longer we delay a deal or can't do a deal at all, it's worse for all the shareholders and the investors and the stock market. yes, a deal that does nothing, it simply keeps taxes where they are right now and doesn't cut entitlements, that's what everybody wants. does matter, believe he, i mean

what's going to happen if we do nothing except keep things exacthe they are now, and just vote to undo the cliff. they'll downgrade the u.s. debt. but that's it. by the way, we have already proven through nine ways of sunday that -- when our credit rating got downgraded last summer. well, bonds went up in price and down in-year-old. -- in yield. so why not do nothing? why doesn't the president say we're just going to keep bonds the way they are. and we're not going to cut entitlements because we know if we don't cut taxes, the republicans will go along with their no tax pledge and the markets will go higher and no one will care, for now. but he told us that's not going to happen, and he got re-elected. what does it matter? it doesn't raise a lot of money.

why didn't he just say that we're taking the able of social security to 6, cutting the military budget. the democrats will be committing political suicide and the republicans. that's why i was hoping that congress would rise above and figure out a more reasonable way to spend less and take in more money over time and get the budget over time. the moronic cliff doesn't hurt. what do we need? i have to use his words because it's like a curse word. compromise. it used to be the american way. compromise, that's considered to be sinking below. you know i favor higher stock prices, that's my mantra. i'm not sure that cutting all these programs quickly, that's what the quick jump would do is the way to get to higher stock

prices, austerity means that tax hikes will go higher. unlike the rest of the 98%, you won't hurt the market as much as if you make everybody pay. the 2% save more and the 98% spent more. but what really hurts is no deal at all. the president ran on a platform of tax increases for the wealthy, he won. the majority of americans voted for him. but the republicans in the house of representatives, hey, they won too, and they're for keeping the taxes low. they won. so how the heck can both sides come together and make a deal? they can't. as long as we're stuck in washington, we're stuck with the lower spending higher tax promise. and then we got wall street. that brings me to apple. i think apple is going down pretty much every day for the simple reason that there are more severals than buyers, but the vast majority of people who

own the stock will be capital gains and they'll be taxing the ira anyway. so does it matter how apple's quarter is? whichive it happens to be the last day of the year, logic is stunningly simple. then it should let up when they can't get the tax break anymore. if i told you that sales taxes are going up, maybe big, i won't say large screen tvs come 2013. wouldn't you go buy one now rather than 2013. if the president were to say that taxes aren't going up, there's no taxes on apple if you sell it, i think the selling would be done immediately n short washington is driving this, not apple, it's an inexpensive stock. here's the bottom line, i would do anything not to focus on washington, anything. but we can't go much higher

without a deal, any deal. and a deal is going to be made or not made on wall street, now washington. and i have to go up there tomorrow. i don't want to do it. given that the president won re-election, and he ran on the fact that he's going raise capital gains, these will what you call facts. meredith in california, meredith. >> caller: hi, sweet jim cramer, from devore, california, thank you so much for helping beginning investors like me. >> well, thank you, that's what this show is about, how can i help? >> my stock is ingersol rand, it's a security tech business and possible announcement of

share buyback program and i would love to have your input. >> a lot of people thought it wasn't enough. i saw this when it came over, i think it was right before the arizona cardinals decided that they were going to throw the game, excuse me, it was more like when the new orleans saints decided they were going to throw the -- it came in the afternoon. what happened is i thought the stock would be 50.5 $50.51 i wau to stay with ingersol rand. we have found when you buy with him, you make money. jude, my home state of new jersey, how are you? >> caller: thank you for helping me make a lot of money and i have a question for you. >> you bet. >> caller: the rumor that beam is going to be bought by a japanese company, is that good?

>> the beam numbers are great. don't buy it on takeout, buy it because their earnings are going higher. let's go to michelle in florida. >> caller: jim, i look forward to your show every week night, it's enlightening and energizing. i have noticed that retail sales are up in china almost 15% and i would love to hear your thoughts about retail stocks and your exposure in china such as tiffany. >> i'm not a fan of tiffany. that stock has been a very, very difficult stock. i do think that you want to look at pch because of the warm weather in america, but on calvin klein, that's the one i think you ought to look at. got to come in, warm weather is going to cause everybody to have jitters. i wish we could forget about politics. until we get a deal, it's bad

news for themarket. even for cheap stock like apple. "mad money" will be right back. tonight, two companies with break through products that are leading the charge. cramer is talking to the ceos of immunojet and seattle genetics, just ahead. and later, reenergized in pipelines, they're america's energy toll road and they can provide investors with a secure source of dividends, but his investment in north dakota's oil rich back and shale continues, cramer's looking for companies that are looking to expand. all coming up on "mad money."

well, if it isn't mr. margin. mr. margin? don't be modest, bob. you found a better way to pack a bowling ball. that was ups. and who called ups? you did, bob. i just asked a question. it takes a long time to pack a bowling ball. the last guy pitched more ball packers. but you... you consulted ups. you found a better way.

that's logistics. that's margin. find out what else ups knows. i'll do that. you're on a roll. that's funny. i wasn't being funny, bob. i know. you won't take our future. aids affects us all. even babies. chevron is working to stop mother-to-child transmission. our employees and their families are part of the fight. and we're winning. at chevron nigeria, we haven't had a reported case in 12 years.

aids is strong. aids is strong. but we are stronger. and aids... ♪ aids is going to lose. aids is going to lose. ♪

moments like this when everybody is terrifieda our economy coiled slide back into a government induced recession next year, i got to start looking at high quality companies that are immunized against this slow economy. for instance biotech companies that can thrive even during a recession. because that's the type of thing you don't cut back on. this week we caught one of those medical conferences that will tell you which ones have the most upside. it's the american academy of pharmaceutical companies -- i'm

highlighting not one but two biotechs. let's start with immunojet. it makes drugs that allow chemotherapy agents to directly target a tumor. immun immunogen rise from 11.50 $11.5 about $18. then at the end of october, the stock got pulverized when we learned that immunogen has a less than optimal royalty anment with this drug. even if the drug becomes a block buster, some people feel that immunogen is going to only get a

small part of the pie. just today the company presented some data on its small cell lung cancer drug. unlike tdm-1, this one is wholly owned by immunog next. it's only in phase 1 development. final phase 2 data not expected until last year. so could it be big? how big? as the company got a number of cancer drugs that could also be big, including one for ovarian cancer and one for lymphoma, immunogen, the stock has given me a 50% run. let's find out more about how these drugs are progressing and where his company is heading. welcome back to "mad money." >> nice to be here, thank you.

>> we are very excited because of the release that you put out late today that talks about a small lung cancer phase two driver in your pipeline. tonight was phase one data, but it looks like you have all the money that could come to you in this, you don't have to share with roche. can you show me what the data showed and why this is so important to the company? >> this is data that came out at the home mow logical con sense. in multiple myeloma, about 80% of multiple mills loma argument. across the patient population, some patient had not received the drugs previously. we saw very good efficacy in the

patients that hadn't received previously, 88% of them showed some level of partial response. some of it undoubtedly due to 901. more importantly, the more difficult patient population is the ones who had receiveded revlomid, and now came into in particular combination study. here about 44% of that population showed some level of response, a very good pr, which is a strong response. and even those that didn't show a response, about 44% of them showed stable disease. what it said to us, looking at it now importantly in combination, it recon firmed to us that we think we have an active agent here. this was an important study from that stand point and it also reaffirmed to us that we can -- from the underlying agent. so we picked up some very good information from this study. >> we no from the ceo of cell

gene, is it possible that this particular combination might prodooz for your company a billion dollars in sales? >> it's hard to say for this combination. what we have done is the multiple myeloma data is very important. what we have done is focus on 901 in small cell lung cancer. that's where we have a small randomized lung cancer. multiple myeloma is a heinous disease. people respond to the therapy, but then the disease progresses, there are a number of therapies available and more coming. so i think that our first entree with 901 would be with squam mus cell lung cancer.

this target is broadly expressed on a number of cancers. so the potential here, if we can show proof of concept is substantial. difficult at this point to say exactly how big. >> let's just go back to tvm-1, i know people were spooked by the economics of it. it is a fabulous drug. i'm just trying to get my arms around the idea that -- this could be just a huge drug and maybe your percentage will end up being a great deal of money? >> i think it's clearly going to be a very successful drug. the data that we have seen thus far in metastatic these is very strong for efficacy and provides them a much better tolerableability compound. you're giving us something that works better and is more tolerable. that just doesn't happen in this space. what we disclosed in our last conference call, is more detail

around the royalty structure, it aligns with the guidance that we provided saying it's roughly a single digit royalty and we believe given the potential of tdm-1 as a compound has a range of developments because it's being developed in metastatic disease, and it will economically deliver a great reward to immunogen and it's share holders. these are wholly separate, there's no way that roche could say that they should own a part of img and 901, this is a pleatly different molecule, right? >> 901 is just one of three completely owned molecules, we have two other phase one compounds that we will have data on in 2013 as well as small lung canner in 2013. we have a fourth coming into the

clinic next year, so they are entirely separate from tdm-1. >> dan, this is great news, you have done a terrific job for people who watch this show, i'm so glad you came on. this is all yours, it's just gigantic, thank you for being on "mad money." >> that's the ceo of immunogen, is that's imgn. they have got a lot in the pipe that is just theirses. i would stay with immunogen and stay with that amount of money. >> america's pipeline, they are america's energy toll road. but an -- cramer's looking for companies that could be ready to expand, don't miss his exclusive with the ceo of n-bridge to see if there's growth in this

pipeline. and later, best medicine? seattle genetics is pioneering ways to help patients fighting cancer to live longer lives. don't miss cramer's interview with its ceo. all coming up on "mad money."

try running four.ning a restaurant is hard, fortunately we've got ink. it gives us 5x the rewards on our internet, phone charges and cable,

plus at office supply stores. rewards we put right back into our business. this is the only thing we've ever wanted to do and ink helps us do it. make your mark with ink from chase. i have obligations. cute tobligations, but obligations.g. i need to rethink the core of my portfolio. what i really need is sleep. introducing the ishares core, building blocks for the heart of your portfolio. find out why 9 out of 10 large professional investors choose ishares for their etfs. ishares by blackrock. call 1-800-ishares for a prospectus which includes investment objectives, risks, charges and expenses. read and consider it carefully before investing. risk includes possible loss of principal. idiocy in washington.

it seems like an -- transport oil from remote areas where it's pumped out of the ground to places where it's refined. the pipeline operators, enb for you home gamers, this is the pine line that operates the most efficient transportation system. we just talked about it in october, on the heels of its very strong analysts. there's been a ton of good news for this company. it's also a $6.2 billion $company. on top of a new railroad joint venture. embridge now has $26 billion

worth of commercial prekts through this year. those projects are fuelling the company's earnings growth which management suggests will be upwards for four years to come. no wonder the stock is only a few cents away from its 52-week high. this stock has only gotten stronger since we last checked in with management. mr. monaco, welcome back to "mad money." >> thanks, jim. glad to be here. >> could you please explain to the american people how there are $26 billion worth of products because there is that much oil and gas in north america that needs to be sent to where it can be used? >> that's right, jim, in fact we know there's been a huge renaissance in oil production, not just in canada from the oil sends, but obviously in the united states and that's fueling the need for more and more

pipeline capacity. at the end of the day, connecting these markets from growing supply, with refinery markets and demand markets means ultimately lower fuel prices for consumers. >> let's talk about that, if we were to use natural gas as a surface vehicle fuel and we got all the oil that you're talking about to the refineries, do we see a world where we could have gasoline back to $2.50? >> well, i'm not sure about $2.50, jim, ultimately the price of oil is determined on the world market, so we're probably going to be aways away from 2.50, but what you will see is better connectivity between supply and deman. >> how does your business work, let's say a bunch of guys wanted to the railroads, a bunch of guys wanted to do pipe. how come it's going to end up being you and how do you beat up the other guys. >> although rail is a very good

interim solution in that it gets product to market very quickly, ultimately we feel that the lowest cost transport for needs to be pipelines. and ultimately that is because we have got the scale and we have got access to the right markets and that should happen once we have got all that tied in. >> now, if you guys are the bests builders a and the other guys who might say, well, jim you're sliding trance canada, but transcanada has a keystone problem. is there are way your company can do exactly what the keystone's are doing or wants to do without damage to the act which furs? >> this goes missed because we have established a link right from western canada all the way to the u.s. gulf coast and by the way, that is a key market because you've got 8 million barrels a day of refining capacity. so we have got a link right now all the way from western canada

to the gulf coast, via or main line, then we have got our spare head flanagan south and that's linked up from cushing all the way into the gulf coast into the market with our sea way project. and by the way, that project is linked up with our partner enterprises. >> i meean why do we need keystone? >> like i said, we have got a lot of crude oil supply coming out of western canada, certainly it's not conduit and producers want other options so that's part of the reason anyway. >> how do you feel about the department of energy study last week that said we ought to be able to export our natural gas? >> natural gas? >> yeah. >> you know, if you look at the pricing of natural gas in north america, it sells way below world gas prices. and ultimately, with con

activity to markets worldwide, it makes sense to do that and to get the world price for natural gas. right now we're selling at a huge discount for natural gas as well as crude oil, in fact, in north america. >> okay, al, continent tall resources for last year say a lot of people say this is going to run out. a lot of people think we're just scratching the surface. which is a more accurate description, scratching the surface or being tapped out in ten years? >> it's somewhere in between, jim, the reality is that the pace of drilling continues to grow out of the balkan, it's a great reservoir, and it's very high quality crude. i think that producers in the area have cracked the code as far as being able to drill up economically and there's probably a lot more room to run in the balkan. >> where is all this natural gas

going to go? because the guys from dominion is out nine years wrchlt is all that natural gas going to end up? >> the natural gas from canada will end up in asian markets. if you think about gas as a long-term fuel that really is going to be, i think a fuel of choice. so exporting natural gas is going to be part of it. certainly feeding the petro chemical demands in the u.s. is going to be a good story. >> thank you for coming and talking to the "mad money" viewers. >> this is the most subsequent best growth pipeline story, you keep raising the dividend, you can take a look at their long-term plan, i like these guys so much.

i president and ceo of embridge. stay with cramer. coming up, are you ready to get charged up? cramer cranks of the voltage and goes electric in an all new hyperactive lightning round. i always wait until the last minute. can i still ship a gift in time for christmas? yeah, sure you can. great. where's your gift? uh... whew. [ male announcer ] break from the holiday stress. ship fedex express by december 22nd for christmas delivery.

it is time, it's time for the lightning round. are you ready, start with the lightning round. i start with sam in florida. sam. >> good evening, professor cramer. >> thank you, what's up? >> you're the best, a big boo-yah from venice, florida on the gulf. >> i do love venice. what's up? >> caller: what is your feeling on first energy. >> first energy has been going down along with the rest of the utilities. you take your first -- don't buy it until it gets to $6. >> i'm going to new york and marc. >> caller: i just know what i

should do with mellonox. >> i want to sell the stock. let's go to lewis in florida. >> caller: jim, boo-yah. i'm interested in northern tier energy. nti. >> i don't trust that yield. i don't trust that yield. let's do more work, the-year-old is gigantic. i think it will end up being a red flag, it's a challenge flag and i think it's going to be a good challenge. let's go to tom in wisconsin. tom? >> caller: hey, jim, i'm calling from a nursing home. i want to ask you about a company rvc, regal bullet corporation. >> listen to me, partner, first of all thank you for calling in. that is a great industrial company, it's done nothing for a long time. i want you to stick with it. it's got a good yield, it's a very well run company, i have

liked it for 35 years. keep it. let's go to jason in virginia. >> caller: i need some help, the stock emed, they reported last month double digit profit, double digit earnings, i'm down 34%. i do add more on this? >> we have to do more on that, we cannot tell you get in and jump in with both feet. i will come in with more at the end of the week. i need to go to mark in ohio. mark? >> caller: emt beganing is a buck -- i don't like pnc bank, they are not been able to make the numbers like i thought, i do not think this is as good a bank as i used to. i'm going to sell that stock. paul in illinois. >> caller: i want to talk about

bsla. the stock is very expensive, the ceo did tweak the other day. i actually like a little longer term view. i do not like tesla, but that does not mean it couldn't go higher. and that, ladies and gentlemen, is the conclusion of the lightning round. >> the lightning round is sponsored by t.d. ameritrade. coming up, best medicine? seattle genetics can finding ways to help americans fighting cancer to live longer lives. don't miss cramer with its cia . get married, have a couple of kids, [ children laughing ] move to the country, and live a long, happy life together where they almost never fight about money. [ dog barks ] because right after they get married, they'll find some retirement people who are paid on salary, not commission.

they'll get straightforward guidance and be able to focus on other things, like each other, which isn't rocket science. it's just common sense. from td ameritrade. customer erin swenson bought from us online today. so, i'm happy. sales go up... i'm happy. it went out today... i'm happy. what if she's not home? (together) she won't be happy. use ups! she can get a text alert, reroute... even reschedule her package. it's ups my choice. are you happy?

i'm happy. i'm happy. i'm happy. i'm happy. i'm happy. happy. happy. happy. happy. (together) happy. i love logistics.

when you're speculating in biotech plans, what we care about more than anything else is data. specifically data from clinical trial results. that's why we love biotech conferences.

right now we're right smack in the middle of the american hematology -- this company is like immunogen. seattle genetics just released a bunch of zeta on their cancer drugs that treats a number of different types of lymphoma. right now seattle genetics is studying the drug to see if it can be used more broadly. this is a battleground stock, it was up 60% in the year. because nothing game changing seems to have happened. seattle genetics again today got slammed. hey, maybe this is a buying opportunity. seattle genetics has a number of intriguing drugs in its pipeline, although they're mostly in early stage

development. however it also has licensing agreements with several good players. glaxosmithkline, pfizer among others. and this company is poised to make money from milestone payments on drugs they have -- and for today's pull back, got to wonder, maybe there's some room to run, so let's talk to clay segow, welcome back to "mad money." >> thank you, jim. a pleasure to be back here. >> all right, clay, walk us through, including some of the data that just came out today that makes seattle genetics more attractive to investors than it was 72 hours ago. >> well, first of all, we put out a lot of data and it really shows that we're helping a diverse set of patients, and that that's our goal is to really make a difference in patients' lives and we're

looking to make it into a blockbuster drug looking into the future. last night we put out a set of data on t-cell lymphomas, and we showed a 100% response rate in front line t-cell lymphomas and the way we saw it in the trial is to get rid of four drugs that causes neurotoxicity, and replace it with drugs that were already approved in the relapse setting and it resulted in an 88% complete remission rate and an objective -- that came out last night and we were delighted with those data. and we just released a press release about tonight's data. that's after market. and tonight's data is from hodge skin lymphoma. this 96% complete response rate is also with lex tox sitity

because we get rid of the worst drugs in the standard chemotherapy, so we see no lung toxicity and we see an improv improved -- >> you already have something that's been approved so you don't have to worry about anything coming along that has a side effect that isn't quite evident now. is the fda a going to look at this and say give us a couple more years of studies and maybe we'll use it, but right now we have something that will work. >> that's exactly what has happened, we have met with the fda and we have what's called a special protocol agreement, it's an spa. and this agreement is for the conduct of a pivotal phase three trial and we have one for hodgkin's lymphoma and one for t-cell lymphoma and the t-cell

lymphoma trial should start within the next month or two and we're really excited to do those trials, get them done and then become the standard of care and really redefine front line therapy for all these patients with two different types of lymphoma. >> when you say front line therapy, how much is currently spent on the system, the cocktail that's used for the front line therapies? >> i can tell you about patient numbers. in front line hodgkin's lymphoma, it's about 10,000 patients a year just in the united states. and if you look at the t-cell market, it's roughly 5,000 to 6,000 patients in the united states. so that market opportunity is substantial. >> you have currently said, you went through your most recent comps calls that jew oar going to have substantial sales next year, so i want to tell an

investor in my show that absolutely wants to buy something, how do you balance flat next year with the possibility of a very exciting pine line for 2014, 2015? how do we view this? >> i think it's a good question, what you're asking. first of all, we didn't provide guidance yet for 2013 formally until february, which is our fourth quarter conference call, so then we'll be clear with what our guidance is for 2013. we look forward to a lot of catalysts coming up, we expect early next year approval in canada, we just recently got approval with our partner, approval in the 27 member countries and the european union. we are submitting early next year two supplemental or sblas with the fda, we expect a plethora of data with more than 10 different trials, in fact we have more than 20 trials under

way, but expecting a lot of data over the next year. and we have a full pipeline of other products, so there really is a lot of catalyst looking forward and we're very excited about how we're helping patients. >> i want you to stay in touch with us because every time, you know, you have made us money, a lot of people, it's money of the most asked about stocks on the lightning round and from the people i see on the street, so please come back when you have more data, because i think it's a very compelling story and i'm glad you came on "mad money." >> i would be delighted to. >> that's the president and ceo of seattle genetics, i know many of you follow it. i like the data, 2013, we don't know if it's going to be flat or not. we just know that mr.'s a lot coming down the pipeline with drugs that could help people a lot. [ male announcer ] citi turns 200 this year.

in that time there've been some good days. and some difficult ones. but, through it all, we've persevered, supporting some of the biggest ideas in modern history. so why should our anniversary matter to you? because for 200 years, we've been helping ideas move from ambition to achievement. and the next great idea could be yours. ♪ [ male announcer ] you build a reputation by not breaking down.

consider the silverado 1500 -- still the most dependable, longest-lasting full-size pickups on the road. and now we've also been recognized for lowest total cost of ownership -- based on important things, like depreciation, fuel, and maintenance costs. and now trade up to get a 2012 chevy silverado all-star edition with a total value of $9,000. from outstanding value to standing the test of time, chevy runs deep.

where do you get your investment ideas anyway? the worst ideas probably come from the business sections of the major newspapers? why are they the worst? simple because everyone reads the business section, because it's the most read. my best ideas tend to come from the other side of the paper, the ones that aren't trying to have investment objectives.

the reporters aren't business writers. that's not what they there for. this weekend, i missed a sad story in the "new york times" about a prank played by a couple of trailian radio jokes to -- royal kate middleton has been recuperating, and that led to a suicide of a nurse that told the -- four years earlier, the daily mirror published a series of photographs of inside buckingham palace, showing that the queen's cereal was brought to the table in tupperware containers. there's more focus on tupperware than the actual thrust of the story. because i interviewed tupperware's ceo on "squawk on

the street." somehow, someone sold the british royal family some tupperware containers and that's a reminder that this family is not a mid level marketing company where the majority of sales stay in the system, the products don't resonate with the most prestigious coast her in the world. when i asked who sold the queen on the containers, he said basically the queen has good taste, so of course she uses tupperware. but unlike herbal life or iowa von, this is a pristine brand and a history of long beating the loftiest of expectations. tupperware is indeed firing on all cylinders. the organic growth is about 6%. and that laps some very difficult 10% comparisons. one of the most difficult stories regarding tupperware is

how the very popular country of indonesia has become a market. indonesia quoted a stunning 30% clip in the most recent quarter, and that was on top of a 50% increase last year. to me these numbers speak to the universality of these numbers and the acceptance that tupperware's product is superior to good news that can be bought in a department store. when i asked him this morning how he can police his company and make sure that a big chunk of his sales don't go to other people whom sellers are trying to recruit as distributors, that's the herbal life model. he made it clear that less than 10% of his customers are sellers. the company spews cash. when i asked him if he would return to capital shareholders in the form of a special dividend. he responded that the board's

ponder just such an action. still another reason to buy this company that is at its 52-week high. >> president obama hits the road to secure his position on the fiscal cliff. but why ral-- this is america.

we don't let frequent heartburn come between us and what we love. so if you're one of them people who gets heartburn and then treats day after day... block the acid with prilosec otc and don't get heartburn in the first place! [ male announcer ] one pill each morning. 24 hours. zero heartburn.

can i still ship a gift in time for christmas? yeah, sure you can. great. where's your gift? uh... whew. [ male announcer ] break from the holiday stress. ship fedex express by december 22nd for christmas delivery. i just want to be sure